Samsung Biologics booth at the BIO International Convention 2024 in San Diego (Courtesy of Yonhap) Samsung Biologics Co., the world’s largest contract drugmaker, has become South Korea’s third most valuable stock on the country’s main bourse, buoyed by strong sales growth and
Researchers at Samsung Biologics' third plant in Songdo, Incheon South Korea's Samsung Biologics Co., the world’s largest contract drugmaker, on Wednesday posted its largest-ever annual sales and operating profit, driven by a steady stream of profitable drug-making contracts for pharmaceu
Celltrion's Vegzelma is a biosimilar of Roche's Avastin, a cancer treatment South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, has emerged as the most-prescribed medicine in Europe.According to globa
Celltrion CEO Seo Jin-seok (left) and Chairman Seo Jeong-jin at the JP Morgan Healthcare Conference in San Francisco SAN FRANCISCO – South Korea’s leading biosimilar drug developer Celltrion Inc. seeks to acquire a domestic health food maker as early as the fourth quarter and plans
SK Biopharmaceuticals CEO Lee Donghoon speaks to the press on the sidelines of the JP Morgan Healthcare Conference in San Francisco on Monday South Korea’s SK Biopharmaceuticals Co. has signed a deal with Brazil’s Eurofarma Laboratórios S.A. to establish a joint venture in th
Celltrion's headquarters in Incheon South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar market, capturing over 50% market share in the six best-selling blockbuster categories.According to global pha